CHC

  • About Us
  • News
  • Coming Up
  • Resources
  • Contact Us
  • Search

New York Times Provides an Analysis of Why Pharmaceutical Companies Should Not Be Barred From Participating in CME

September 8, 2010

Read this article on Tom Sullivan’s Policy and Medicine blog 

…then please come cymbalta without a prescription back here and comment.discount buy viagra

Posted in Legislative

Post navigation

Associations React to NIH-Proposed Conflict of Interest Rules
Coalition Supports FDA Revision of Patient Information Requirements

Categories

  • CHC News
  • Courts/First Amendment
  • Data Privacy
  • Drug Pricing
  • DTC Advertising
  • General
  • Legislative
  • Off-label Promotion
  • Point of Care
  • Regulatory/FDA
  • Uncategorized
  • Washington Focus

Recent Posts

  • Could Burr’s New User Fee Bill Lead to Timely Passage of Legislation?
  • FDA Proposes Increased Consumer Access to Nonprescription Drugs, with Conditions
  • OPDP: Risk, Efficacy Claims for Cholesterol Drug in Doctor Promotion Are False/Misleading
  • HHS Formally Withdraws SUNSET Final Rule
  • OPDP Reorg, Outreach Efforts Designed to Improve Relationship with Industry

Tags

ad tax Advertising Coalition CDER CMS coalition for healthcare communication conflict of interest Congress COVID-19 data privacy DDMAC drug prices in DTC ads drug pricing DTC DTC advertising DTC advertising FDA FDA Commissioner FDA Draft Guidance FDA enforcement FDA social media free speech gifts to physicians HHS John Kamp Jon Bigelow kamp Kate Rawson legislation litigation marketing off-label off-label communication omission of risk OPDP OPDP enforcement PhRMA regulation Risk Information rx data Scott Gottlieb social media sunshine act Untitled Letter Warning Letter Wayne Pines
CHC

Smart Brief
© 2021 Coalition for Healthcare Communication. All rights reserved.